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Summary Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of
tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise.
The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly),
1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting
toxicity was the same and as no partial or complete responses were identified, we do not recommend that
further trials of elactocin are performed.
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Elactocin is a novel anti-tumour antibiotic (Schaumberg
et al., 1984) that has high potency against a range of
experimental tumours, including leukaemia L1210, Lewis
lung carcinoma, human colon xenograft HCT-8 and human
lung carcinoma A-549. It has activity against P388, resistant
to doxorubicin, amsacrine and mitoxantrone (Leopold et al.,
1984; Tunac et al., 1985; Roberts et al., 1986). Studies at the
National Cancer Institute confirmed that it had significant
activity against solid murine tumours and that it was
schedule dependent, being more effective on a day 1 to 5
schedule. Elactocin inhibits DNA synthesis and in a dose-
dependent manner inhibits DNA polymerase. Its novel
structure is shown in Figure 1. The murine toxicology of
elactocin was performed under the auspices of the Cancer
Research Campaign phase I/II subcommittee. The maximum
tolerated dose (MTD) of the single intraperitoneal dose of
elactocin was 11.67 mg m-2. Elactocin was much more toxic
when given on repeat dosing, inducing a severe peritonitis,
and when administered weekly x 4 the MTD was
0.12mg 2.
Patients and methods
Patients with advanced refractory cancer with normal organ
function were entered in a phase I trial after written informed
consent had been obtained. Elactocin was administered
intravenously in the formulation of 1 mg ml-' in absolute
ethanol diluted with polyfusor phosphate at pH 7.4 (Slack et
al., 1990). A total of 33 patients were entered in the phase I
trial (19 males, 14 females with a median age of49 years). The
diagnoses in these patients were: colon 8, ovary 4, melanoma
4, glioma 3, sarcoma 3, pancreas 2 and single patients with a
variety of other cancers. Plans to measure elactocin in patient
samples proved not possible owing to interference from other
fatty acids in the serum of patients. Therefore no pharmacol-
ogy was performed during the phase I study.
Results
The starting dose on the single administration schedule was
0.1 mg m-2 once every 3 weeks and was escalated to a
maximum dose of 4 mg m-2 (Table I). Dose-limiting toxicity
was a combination of nausea and vomiting and profound
anorexia and malaise. In order to try and minimise these
side-effects, patients were given elactocin as a 24 h infusion
once every 3 weeks at doses of 3 and 4 mg m-2. Again
gastrointestinal side-effects and profound malaise and
anorexia were dose limiting. Administration of 4 mg m-2
split over 5 days induced a similar toxicity pattern. Elactocin
given as a 1 h infusion weekly in doses between 1.5 and
4 mg m-2 again induced a similar toxicity profile of nausea
and vomiting and marked malaise and anorexia. One patient
received a 5 day continuous infusion of elactocin at
2.5 mg m-2 total dose. The degree of anorexia and malaise
in this patient and in others given the maximum dose was
unusually marked, requiring bed rest and intravenous
hydration for up to 1 week after elactocin administration.
The only possible significant biochemical abnormality seen in
these patients was a rise in transaminases in several patients
which could have been drug related.
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Figure 1 NSC-364372D (PD114,720; elactocin).
Table I Elactocin therapy
Number ofpatients
Number (including
Dose level of escalations
(mg m-2) Schedule courses within patient)
0.1 1 h infusion every 3 weeks 1 1
0.5 1 1
1.0 6 4
2.0 3 2
3.0 1 1
4.0 1 1
Total 13 10
3.0 24 h infusion every 3 weeks 2 2
4.0 3 2
Total 5 4
4.0 1 h infusion daily for 5 days 2 1
every 3 weeks
Total 2 1
1.5 1 h infusion weekly 22 5
2.0 16 5
2.5 18 5
3.0 19 7
4.0 6 3
Total 81 25
2.5 Continuous 5 day infusion 1 1
Total 1 1
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There were no consistent biochemical abnormalities
induced by elactocin to account for the dose-limiting
toxicity. It is unlikely that the principal toxicity was in the
gut since vomiting in many patients was much less
pronounced than anorexia. While no obvious direct toxicity
to the central nervous system (CNS) was seen, such as ataxia,
drowsiness or headaches, the most likely target site for the
profound anorexia possibly was the CNS itself.
No partial response was seen in this group of patients.
Hints of clinical activity were seen in several patients
including an adenocarcinoma of the epiglottis, a transient
fall in CA125 levels in a patient with ovarian adenocarcino-
ma, a slight fall in human chorionic gonadotrophin
concentration in a patient with a gestational trophoblastic
tumour, and one patient with a sarcoma had brief disease
stabilisation.
In conclusion, elactocin has an unusual toxicity profile
inducing marked malaise and anorexia with relatively little
side-effects on other tissues apart from the gastrointestinal
tract. No schedule could be devised which was sufficiently
well tolerated to recommend for further clinical development.
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